| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Black Diamond Therapeutics, Inc. is a biotechnology enterprise dedicated to discovering, advancing, and bringing to market therapeutic agents specifically designed for patients with genetically characterized tumors. A core part of its pipeline is BDTX-189, an irreversible small molecule inhibitor. This compound is engineered to neutralize oncogenic proteins driven by non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) driver mutations. The firm is also progressing BDTX-1535, a …
Over the last 12 months, insiders at Black Diamond Therapeutics, Inc. have bought $0 and sold $0 worth of Black Diamond Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Black Diamond Therapeutics, Inc. have bought $13.99M and sold $4.52M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 400,000 shares for transaction amount of $934,080 was made by BIOTECH GROWTH N V (10 percent owner) on 2023‑10‑17.
| 2025-03-19 | Sale | BIOTECH GROWTH N V | 10 percent owner | 5.78M 12.3106% | $2.07 | $12M | +50.58% | |
| 2024-08-28 | Sale | Versant Venture Capital VI, L.P. | 10 percent owner | 221,600 0.3894% | $6.32 | $1.4M | -61.22% | |
| 2023-10-17 | BIOTECH GROWTH N V | 10 percent owner | 400,000 0.7707% | $2.34 | $934,080 | +100.85% | ||
| 2023-07-05 | Behbahani Ali | director | 1M 2.8199% | $5.00 | $5M | -25.62% | ||
| 2023-07-05 | RA CAPITAL MANAGEMENT, L.P. | director | 935,850 2.639% | $5.00 | $4.68M | -25.62% | ||
| 2023-06-30 | BIOTECH GROWTH N V | 10 percent owner | 1M 2.7138% | $5.00 | $5M | -28.71% | ||
| 2023-06-27 | Sale | Epstein David M. | SEE REMARKS | 25,000 0.0743% | $6.70 | $167,500 | -41.50% | |
| 2023-06-27 | BIOTECH GROWTH N V | 10 percent owner | 1.74M 4.2378% | $5.49 | $9.56M | -41.50% | ||
| 2022-12-22 | Ni Fang | SEE REMARKS | 36,363 0.0972% | $1.28 | $46,596 | +73.48% | ||
| 2022-12-21 | Ni Fang | SEE REMARKS | 20,000 0.0546% | $1.29 | $25,770 | +74.62% | ||
| 2022-10-31 | BIOTECH GROWTH N V | director | 99,801 0.268% | $2.25 | $224,912 | -6.06% | ||
| 2022-10-28 | BIOTECH GROWTH N V | director | 172,974 0.4696% | $2.18 | $376,962 | -1.58% | ||
| 2022-10-27 | BIOTECH GROWTH N V | director | 191,678 0.5124% | $1.87 | $359,224 | +12.95% | ||
| 2022-10-21 | BIOTECH GROWTH N V | director | 87,850 0.2313% | $1.51 | $132,750 | +37.97% | ||
| 2022-10-20 | BIOTECH GROWTH N V | director | 53,734 0.144% | $1.42 | $76,345 | +49.32% | ||
| 2022-10-19 | BIOTECH GROWTH N V | director | 77,689 0.2096% | $1.32 | $102,775 | +61.48% | ||
| 2022-06-29 | Ni Fang | SEE REMARKS | 25,000 0.0681% | $2.44 | $61,018 | -16.60% | ||
| 2022-04-27 | BB BIOTECH AG | 150,000 0.4047% | $2.66 | $399,480 | -22.79% | |||
| 2022-04-18 | BB BIOTECH AG | 150,000 0.4099% | $3.29 | $493,935 | -35.24% | |||
| 2022-04-12 | BB BIOTECH AG | 150,000 0.4078% | $3.42 | $513,600 | -37.46% |
| Behbahani Ali | director | 4448757 7.7637% | $8.05M | 2 | 0 | <0.0001% |
| BB BIOTECH AG | 4438402 7.7457% | $8.03M | 3 | 0 | <0.0001% | |
| Versant Venture Capital VI, L.P. | 10 percent owner | 3726341 6.503% | $6.74M | 1 | 28 | <0.0001% |
| RA CAPITAL MANAGEMENT, L.P. | director | 3213828 5.6086% | $5.82M | 1 | 0 | <0.0001% |
| BIOTECH GROWTH N V | 10 percent owner | 2733547 4.7704% | $4.95M | 9 | 1 | +10.21% |
| Shah Rajeev M. | director | 1924164 3.3579% | $3.48M | 1 | 0 | <0.0001% |
| Bolzon Bradley J PhD | 874099 1.5254% | $1.58M | 1 | 27 | <0.0001% | |
| Flynn James E | 10 percent owner | 778790 1.3591% | $1.41M | 1 | 0 | <0.0001% |
| Ni Fang | SEE REMARKS | 125389 0.2188% | $226,954.09 | 3 | 0 | |
| Hatzis-Schoch Brent | See Remarks | 8400 0.0147% | $15,204.00 | 1 | 9 | <0.0001% |
| INGRAM ROBERT ALEXANDER | director | 5000 0.0087% | $9,050.00 | 1 | 0 | <0.0001% |
$5,552,811 | 165 | 5.84% | $106.2M | |
$1,701,941 | 56 | 17.58% | $93.09M | |
$66,137,559 | 49 | 6.29% | $89.66M | |
$77,146,704 | 43 | 13.28% | $93.12M | |
$130,095 | 43 | 45.19% | $111.24M |
| Increased Positions | 64 | +69.57% | 8M | +20.6% |
| Decreased Positions | 38 | -41.3% | 9M | -23.07% |
| New Positions | 26 | New | 3M | New |
| Sold Out Positions | 12 | Sold Out | 3M | Sold Out |
| Total Postitions | 118 | +28.26% | 38M | -2.46% |
| T. Rowe Price Investment Management, Inc. | $26,753.00 | 18.85% | 10.74M | +231,973 | +2.21% | 2025-09-30 |
| Vestal Point Capital, Lp | $13,820.00 | 9.74% | 5.55M | -50,000 | -0.89% | 2025-09-30 |
| Nea Management Company, Llc | $11,077.00 | 7.81% | 4.45M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $5,450.00 | 3.84% | 2.19M | +85,825 | +4.08% | 2025-09-30 |
| Tang Capital Management Llc | $5,155.00 | 3.63% | 2.07M | 0 | 0% | 2025-09-30 |
| Marshall Wace, Llp | $3,235.00 | 2.28% | 1.3M | +561,333 | +76.07% | 2025-09-30 |
| Siren, L.L.C. | $2,606.00 | 1.84% | 1.05M | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $2,560.00 | 1.8% | 1.03M | -62,771 | -5.75% | 2025-09-30 |
| Arrowstreet Capital, Limited Partnership | $2,233.00 | 1.57% | 896,853 | +758,709 | +549.22% | 2025-09-30 |
| Millennium Management Llc | $2,117.00 | 1.49% | 850,331 | -94,522 | -10% | 2025-09-30 |